Ballentine Partners LLC increased its stake in Allergan PLC. (NYSE:AGN) by 5.2% during the first quarter, Holdings Channel reports. The fund owned 2,875 shares of the company’s stock after buying an additional 142 shares during the period. Ballentine Partners LLC’s holdings in Allergan PLC. were worth $688,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AGN. Crestwood Advisors Group LLC acquired a new position in Allergan PLC. during the first quarter worth approximately $103,000. Feltz Wealth PLAN Inc. acquired a new position in Allergan PLC. during the first quarter worth approximately $107,000. Enterprise Financial Services Corp boosted its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC boosted its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. 84.77% of the stock is currently owned by institutional investors.

Allergan PLC. (NYSE AGN) traded up 0.31% during mid-day trading on Friday, reaching $232.92. The company’s stock had a trading volume of 843,449 shares. The company’s 50-day moving average price is $246.34 and its 200 day moving average price is $238.00. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a market capitalization of $78.07 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.35 earnings per share. On average, equities analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

ILLEGAL ACTIVITY WARNING: “Ballentine Partners LLC Has $688,000 Stake in Allergan PLC. (NYSE:AGN)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/11/ballentine-partners-llc-has-688000-stake-in-allergan-plc-nyseagn.html.

A number of research analysts have recently commented on AGN shares. Zacks Investment Research raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a research note on Wednesday, May 10th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Royal Bank Of Canada upped their target price on Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Citigroup Inc. upped their target price on Allergan PLC. to $261.00 and gave the company a “buy” rating in a research note on Monday, April 24th. Eight equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $274.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.